12/3
05:37 am
mnkd
Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset [Yahoo! Finance]
Low
Report
Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset [Yahoo! Finance]
12/1
08:05 am
mnkd
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
Low
Report
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
11/24
10:02 am
mnkd
MannKind (NASDAQ:MNKD) was given a new $9.00 price target on by analysts at Truist Financial Corporation.
Low
Report
MannKind (NASDAQ:MNKD) was given a new $9.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
mnkd
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/13
09:53 am
mnkd
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Medium
Report
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
11/11
04:32 pm
mnkd
MannKind to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
Low
Report
MannKind to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
11/11
04:05 pm
mnkd
MannKind to Present at the Jefferies Global Healthcare Conference
Low
Report
MannKind to Present at the Jefferies Global Healthcare Conference
11/11
10:31 am
mnkd
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.50. They now have an "outperform" rating on the stock.
Low
Report
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.50. They now have an "outperform" rating on the stock.
11/11
09:44 am
mnkd
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Wells Fargo & Company from $10.00 to $8.00. They now have an "overweight" rating on the stock.
Low
Report
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Wells Fargo & Company from $10.00 to $8.00. They now have an "overweight" rating on the stock.
11/10
01:22 pm
mnkd
MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript [Seeking Alpha]
Low
Report
MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript [Seeking Alpha]
11/10
01:05 pm
mnkd
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/10
08:40 am
mnkd
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease [Yahoo! Finance]
Medium
Report
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease [Yahoo! Finance]
11/10
08:00 am
mnkd
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
Medium
Report
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
11/8
12:25 pm
mnkd
MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ... [Yahoo! Finance]
Medium
Report
MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ... [Yahoo! Finance]
11/8
11:46 am
mnkd
MannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline Expansion [Yahoo! Finance]
Medium
Report
MannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline Expansion [Yahoo! Finance]
11/6
09:40 pm
mnkd
Will Rising Costs and Revenue Growth Shift MannKind's (MNKD) Long-Term Investment Outlook? [Yahoo! Finance]
Low
Report
Will Rising Costs and Revenue Growth Shift MannKind's (MNKD) Long-Term Investment Outlook? [Yahoo! Finance]
11/6
09:00 am
mnkd
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
Medium
Report
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
11/5
08:05 am
mnkd
MannKind Non-GAAP EPS of $0.07 beats by $0.04, revenue of $82.13M beats by $1.88M [Seeking Alpha]
Neutral
Report
MannKind Non-GAAP EPS of $0.07 beats by $0.04, revenue of $82.13M beats by $1.88M [Seeking Alpha]
11/5
08:00 am
mnkd
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
11/1
11:12 am
mnkd
Great week for MannKind Corporation (NASDAQ:MNKD) institutional investors after losing 22% over the previous year [Yahoo! Finance]
Low
Report
Great week for MannKind Corporation (NASDAQ:MNKD) institutional investors after losing 22% over the previous year [Yahoo! Finance]
10/29
04:05 pm
mnkd
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
Low
Report
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
10/20
08:14 am
mnkd
MannKind (NASDAQ:MNKD) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $10.00 price target on the stock.
Low
Report
MannKind (NASDAQ:MNKD) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $10.00 price target on the stock.
10/13
08:20 am
mnkd
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes [Yahoo! Finance]
Low
Report
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes [Yahoo! Finance]
10/13
08:07 am
mnkd
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
10/13
08:05 am
mnkd
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
Medium
Report
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes